Market research
1N7.F Nevro Corp
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 203M
- P/E ratio
- Not available
- Analyst target
- 139.62
- Dividend yield
- Not available
- Beta
- 0.82
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US64157F1030
- Market cap
- 203M
- P/E ratio
- Not available
- Analyst target
- 139.62
- Dividend yield
- Not available
- Beta
- 0.82
About
About Nevro Corp
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS systems. It also offers Senza HFX iQ platform that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system. In addition, the company provides HFX AdaptivAI, a pain management platform that powers the HFX iQ SCS system, as well as surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is based in Redwood City, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 1N7.F discussion.
5 years, 4 months ago
Nevro Corp is currently in a long term downtrend where the price is trading 4.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.0.
Nevro Corp's total revenue sank by 4.1% to $110M since the same quarter in the previous year.
Its net income has increased by 48.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 161.9% to $9M since the same quarter in the previous year.
Based on the above factors, Nevro Corp gets an overall score of 3/5.